GlassScriptPhysician profile
Neil Lyman
NPI 1619078367
$5,157.35
in general payments reported to CMS, 2019-2025
28 companies · $767 in 2025
The $767 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $290 · 2021: $444 · 2022: $884 · 2023: $1,083 · 2024: $1,118 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.35 |
| Education | $109.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $958.09 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $947.94 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $591.03 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $355.75 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $274.26 | 2022-2024 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $258.47 | 2021-2024 | Rayaldee |
| Ardelyx, INC. | $239.22 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $219.44 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Aurinia Pharma U.S., INC. | $160.38 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $132.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $116.31 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.94 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $104.18 | 2022-2023 | Tarpeyo |
| Horizon Therapeutics Plc | $84.89 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $84.72 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $80.42 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $70.29 | 2019-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.74 | 2024 | Jardiance |
| Genzyme Corporation | $62.80 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $47.60 | 2024-2025 | Edarbyclor, Edarbi |
| Akebia Therapeutics INC | $45.47 | 2021-2024 | Auryxia, Vafseo |
| Genentech USA, INC. | $41.29 | 2019 | |
| Novo Nordisk INC | $29.36 | 2022 | |
| Acist Medical Systems, INC. | $22.42 | 2022 | |
| Invivyd INC | $17.28 | 2025 | Pemgarda |
| Cormedix INC. | $16.43 | 2025 | Defencath |
| Mallinckrodt Hospital Products INC. | $13.30 | 2023 | Acthar |
| Shire North American Group INC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Lyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.